Background: Biomarkers are useful in the early detection and risk stratification of metabolic syndrome (MetS) patients. Serum uric acid (SUA) is the end metabolite product of purine degradation and is the most abundant antioxidant in human plasma, as it protects against free radical oxidative damage. Objective: To investigate the potential association between serum uric acid (sUA) and MetS. Patients and Methods: A prospective case-control study was conducted in Cardiac Unit, Zagazig University Children's Hospital, during the period from February 2019 until August 2019. Our Study included 26 patients with metabolic syndrome who were randomly selected from 129 random obese pediatric patients according to waist circumference and BMI with percentage of 20.1%. We enrolled matched control with same number. Results: Cases were significantly higher concerning uric acid. We found significantly positive correlation between body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglycerides (TG), total cholesterol, low-density lipoproteins (LDL) and serum uric acid (SUA), while significant negative correlation of serum uric acid and high density lipoprotein (HDL-C). According to ROC curve analysis, the AUC of SUA for detection of metabolic patient with best cutoff value > 4.3 with sensitivity 70% and specificity 96.3%, and this was maximizing sensitivity and specificity to predict future metabolic syndrome and their area under the curve was 0.79. Conclusion: Serum uric acid showed a significant correlation with components of metabolic syndrome making it a potent biomarker for diagnosing of metabolic syndrome patients in coming years.